Literature DB >> 12913723

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

Wayne J G Hellstrom1, James W Overstreet, Albert Yu, Khalil Saikali, Wei Shen, Charles M Beasley, Vish S Watkins.   

Abstract

PURPOSE: We assessed the effects on spermatogenesis of placebo vs 10 or 20 mg tadalafil administered daily for 6 months to healthy men and men with mild erectile dysfunction.
MATERIALS AND METHODS: In 2 studies 421 healthy men or men with mild erectile dysfunction who were 45 years or older and met semen criteria derived from WHO reference values were randomized to 6 months of treatment with placebo (101) or 10 mg tadalafil (103), or to placebo (106) or 20 mg tadalafil (111). Semen samples and serum for reproductive hormones (testosterone, luteinizing hormone and follicle-stimulating hormone) were collected at baseline, after 3 months and at the end of treatment.
RESULTS: Tadalafil had no adverse effects on spermatogenesis, as assessed by sperm concentration, sperm count per ejaculate, percent sperm motility, normal morphology or serum reproductive hormones. Tadalafil was well tolerated. Common adverse events were headache, dyspepsia and back pain.
CONCLUSIONS: Chronic daily administration of tadalafil at doses of 10 and 20 mg for 6 months had no adverse effects on spermatogenesis or on reproductive hormones in men older than 45 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913723     DOI: 10.1097/01.ju.0000081053.97792.da

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Practical semen analysis: from A to Z.

Authors:  Charlene Brazil
Journal:  Asian J Androl       Date:  2010-01       Impact factor: 3.285

Review 3.  Daily dosing of PDE5 inhibitors: where does it fit in?

Authors:  King Chien Joe Lee; Gerald B Brock
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

Review 4.  Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Alberto Briganti; Andrea Salonia; Federico Deho'; Giuseppe Zanni; Luigi Barbieri; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

Review 5.  Adverse effects of common medications on male fertility.

Authors:  Mary K Samplaski; Ajay K Nangia
Journal:  Nat Rev Urol       Date:  2015-06-23       Impact factor: 14.432

Review 6.  An overview of the diagnosis and treatment of erectile dysfunction.

Authors:  Sivaprakasam Sivalingam; Hashim Hashim; Hartwig Schwaibold
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

Review 8.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Erectile dysfunction: management update.

Authors:  Luke Fazio; Gerald Brock
Journal:  CMAJ       Date:  2004-04-27       Impact factor: 8.262

Review 10.  Tadalafil in the treatment of erectile dysfunction.

Authors:  Anthony J Bella; Gerald B Brock
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.